The Medicare agency has decided to terminate several payment demonstration projects, including an initiative aimed at providing $2 generic drugs. This decision includes the cancellation of eight payment trials, which is expected to result in savings of approximately $750 million. The Centers for Medicare & Medicaid Services (CMS) has opted to pare down its payment model portfolio, strategically streamlining its operations by ending four Medicare pay models ahead of schedule. These changes reflect ongoing adjustments within the Medicare Innovation Center as it seeks to optimize its financial strategies.